Please assess the completion status of the following clinical trial:

Trial Title: Prevalence Studies After Triple Drug Therapy for Lymphatic Filariasis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 5 years (males and females)~* Able to provide informed consent, or parental/guardian consent for young children, and assent for older children~Exclusion Criteria:~* Unable or unwilling to provide informed consent or (for minors) lacking parental/guardian consent to participate in the study

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 2-Drug Treated Communities (Type: None): Communities who were treated with diethylcarbamazine and albendazole (DA) mass drug administration during the safety study entitled Community Based Safety Study of 2-drug (DA) versus 3-drug (IDA) Therapy for Lymphatic Filariasis.
- 3-Drug Treated Communities (Type: None): Communities who were treated with ivermectin, diethylcarbamazine and albendazole (IDA) mass drug administration during the safety study entitled Community Based Safety Study of 2-drug (DA) versus 3-drug (IDA) Therapy for Lymphatic Filariasis.

Based on this trial design, predict the completion outcome and termination type (if applicable).